VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop
tumor cells from dividing so they stop growing or die.
PURPOSE: This phase I trial is studying the side effects and best dose of VNP40101M in
treating young patients with recurrent, progressive, or refractory primary brain tumors.